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Background
Patients receiving anti-TNF-a therapy
for rheumatic or chronic inﬂammatory
bowel diseases are at higher risk of develop-
ing tuberculosis during treatment than pa-
tients with similar diseases not receiving
anti-TNF-a therapy or subjects in the sur-
rounding population [1–3]. As most cases ap-
pear to be secondary to reactivation from a
state of latent infection and not de novo infec-
tion, screening of patients for tuberculosis
and latent tuberculosis infection is recom-
mended before initiating anti- TNF-a ther-
apy [4, 5].
Preventive treatment should be offered
to all patients with evidence of latent tuber-
culosis infection before starting any anti-
TNF-a therapy [6], even if it does not ap-
pear to offer complete protection [7], while
patients with signs of active tuberculosis
should be offered a full course of treatment.
Various recommendations and guide-
lines have been issued on screening for latent
tuberculosis infection. They are traditionally
based on history, chest x-ray (CXR) and tu-
berculin skin test (TST). However, TST has
several disadvantages. Its speciﬁcity is low,
false positive results being common in BCG-
vaccinated subjects or due to a booster effect
[8, 9]. Its sensitivity is also lower in immuno-
suppressed patients than in healthy subjects
[10, 11], and some patients may therefore
have false negative TST. Furthermore, TST
is poorly reproducible, requires two visits for
its performance (for application and reading)
and is subject to observer error. Finally, the
limit above which the TST is considered
positive (i.e. indicative of latent infection) is
unclear and actually differs between coun-
tries and guidelines (5 to 10 mm).
Two in vitro tests have been developed
which detect gamma-interferon (g-IFN) re-
leased by T-lymphocytes sensitised to spe-
ciﬁc antigens of M. tuberculosis. These tests
(Quantiferon-TB® Gold [Cellestis] and T-
SPOT.TB® [Oxford Immunotec]) have a
better sensitivity than TST in immunocom-
promised subjects [11–13] and a higher
speciﬁcity, as they are not inﬂuenced by prior
vaccination with BCG or contact with non-
tuberculous mycobacteria [13, 14]. False-
negative and indeterminate results have been
observed in rare cases with both tests, but are
less frequent than with TST [15, 16]. How-
ever, and despite the evidence of better per-
formance of interferon gamma release assays
(IGRA) than of TST, neither test has been
incorporated into some guidelines for the
screening of latent infection before anti-
TNF-a therapy [17]. The cost-effectiveness
of screening for latent infection with IGRA
instead of TST has been demonstrated [18,
19]. The new guidelines of the Swiss Lung
Association and the Federal Ofﬁce of Public
Health have deﬁned the indications for
IGRA tests for the detection of latent tuber-
culosis infection [6] (available online at
www.tbinfo.ch)
Recommendations
A group of experts in rheumatology, gas-
troenterology and pneumology met in Berne
on 19 September 2006 to evaluate the current
arguments in favour of IGRA and their incor-
poration into recommendations for tubercu-
losis screening before prescription of anti-
TNF-a therapy, and decided to issue Swiss
recommendations based on current knowl-
edge and literature and their own experience
of using IGRA tests in this setting.
After review of the existing literature,
the experts agreed that:
1. A deﬁnite risk of tuberculosis exists with
anti-TNF agents, and all patients should
be screened for tuberculosis and latent
tuberculosis infection prior to any anti-
TNF-a therapy.
2. The screening should be based on his-
tory, chest x-ray and an IGRA test.
a. History: a detailed history of exposure
to or prior treatment for tuberculosis,
considering the risk associated with
birthplace or country of origin or res-
idence in special environments in-
volving increased risk of TB contact
(prisons, shelters).
b. Chest x-ray: a single PA chest x-ray
for detection of past or present tuber-
culosis.
c. IGRA test.
3. Use of TST is no longer recommended
for screening in view of the limitations
mentioned.Even a history of positiveTST
should be conﬁrmed by an IGRA test.
4. Patients with abnormal x-ray ﬁndings
suggestive of past tuberculosis should
undergo complete clinical and bacterio-
logical testing to rule out or conﬁrm ac-
tive tuberculosis. Patients with active tu-
berculosis should receive a full course of
antituberculosis treatment. Anti-TNF-
a therapy can be resumed once the pa-
tient is under antituberculous treatment.
5. Preventive treatment according to the
current recommendations of the Swiss
Lung Association (isoniazid 300 mg/day
for 9 months or rifampicin 10 mg/kg
daily for 4 months) [6] should be pre-
scribed for any patient considered to be
at signiﬁcant risk of reactivation of la-
tent tuberculosis infection deﬁned as
any of the following:
a. A positive IGRA test (unanimous
opinion)
b. An abnormal X-ray suggestive of past
tuberculosis not adequately treated
without current evidence of activity
(majority of experts and BTS Recom-
mendations)
c. A history of signiﬁcative prior expo-
sure to tuberculosis without adequate
treatment (majority of experts and
BTS Recommendations) Patients fol-
lowing preventive treatment for latent
infection may receive anti-TNF-a
therapy. Current practice is to delay
introduction of anti-TNF-a therapy
for one month following preventive
treatment.
6. Screening and preventive treatment do
not offer complete protection, and pa-
tients under anti-TNF-a therapy
should be followed up clinically for
signs of tuberculosis reactivation. There
are no data to recommend repeated
IGRA testing if the result is positive, but
they could be useful in suspect cases or if
a patient with a negative test result is
newly exposed to tuberculosis.
7. In the rare event of an indeterminate
test result it is possible that the patient’s
lymphocytes do not produce interferon-
gamma. If the indeterminate result per-
sists despite repetition of the test, the
need for preventive treatment is deter-
mined solely by history and chest x-ray
ﬁndings; in this setting a cautious ap-
proach is strongly recommended.
Conclusions
Screening for latent tuberculosis infec-
tion is indicated prior to the administration
of anti- TNF-a therapy. Due to the better
sensitivity and speciﬁcity of IGRA tests, their
incorporation into current recommendations
should serve to detect more cases at risk for
reactivation of latent tuberculosis infection
and to prevent unnecessary prophylaxis with
its potentially adverse effects in patients with
false-positive TTS.
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